Ara
Toplam kayıt 4, listelenen: 1-4
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-tine treatment in HER2-negative advanced gastric cancer
(American Society of Clinical Oncology, 2014)
…
Clinical importance of discordance in hormone receptor and HER2/NEU status after neoadjuvant chemotherapy in breast cancer
(Elsevier, 2014)
Aim: Neoadjuvant chemotherapy (NAC) is used longer for both locally advanced breast cancer and early stage to increase breast conservation. Discordance of the hormone receptor (HR) status was reported to be 8-33% of the ...
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer
(Asian Pacific Organization for Cancer Prevention, 2014)
Background: Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer. However, substantial toxicity has limited its ...
Important factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey
(S. Karger AG, 2014)
Introduction: In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect ...